State Street
VTVT icon

State Street’s vTv Therapeutics VTVT Stock Holding History

State Street’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$462K Buy
12,266
+1,600
+15% +$55.5K ﹤0.01% 3613
2026
Q1 		$423K Buy
+10,666
New +$387K ﹤0.01% 3702
2023
Q4 		– Sell
-3,369
Closed -$64.4K – 4495
2023
Q3 		$64.4K Hold
3,369
– – ﹤0.01% 4223
2023
Q2 		$99.7K Hold
3,369
– – ﹤0.01% 4240
2023
Q1 		$109K Hold
3,369
– – ﹤0.01% 4301
2022
Q4 		$87.9K Hold
3,369
– – ﹤0.01% 4407
2022
Q3 		$131K Sell
3,369
-1,785
-35% -$70.3K ﹤0.01% 4342
2022
Q2 		$155K Buy
5,154
+3,756
+269% +$96.3K ﹤0.01% 4323
2022
Q1 		$40K Sell
1,398
-9
-0.6% -$270 ﹤0.01% 4834
2021
Q4 		$56K Sell
1,407
-135
-9% -$7.25K ﹤0.01% 4682
2021
Q3 		$94K Sell
1,542
-720
-32% -$54.3K ﹤0.01% 4562
2021
Q2 		$206K Sell
2,262
-4,707
-68% -$477K ﹤0.01% 4208
2021
Q1 		$786K Buy
6,969
+2,551
+58% +$251K ﹤0.01% 3673
2020
Q4 		$329K Buy
4,418
+24
+0.5% +$1.84K ﹤0.01% 3695
2020
Q3 		$311K Sell
4,394
-16
-0.4% -$1.41K ﹤0.01% 3623
2020
Q2 		$397K Buy
+4,410
New +$435K ﹤0.01% 3569
2018
Q2 		– Sell
-2,606
Closed -$424K – 3802
2018
Q1 		$424K Sell
2,606
-187
-7% -$45.8K ﹤0.01% 3454
2017
Q4 		$673K Buy
2,793
+313
+13% +$70.2K ﹤0.01% 3413
2017
Q3 		$594K Buy
2,480
+30
+1% +$5.98K ﹤0.01% 3450
2017
Q2 		$486K Buy
2,450
+49
+2% +$10.2K ﹤0.01% 3423
2017
Q1 		$630K Buy
2,401
+253
+12% +$57.7K ﹤0.01% 3347
2016
Q4 		$415K Sell
2,148
-92
-4% -$21.1K ﹤0.01% 3415
2016
Q3 		$645K Buy
2,240
+134
+6% +$32.3K ﹤0.01% 3257
2016
Q2 		$488K Buy
2,106
+575
+38% +$132K ﹤0.01% 3394
2016
Q1 		$316K Buy
1,531
+150
+11% +$37.3K ﹤0.01% 3428
2015
Q4 		$376K Buy
+1,381
New +$388K ﹤0.01% 3390

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's VTVT Position: Q2 2026 in Review

State Street increased its vTv Therapeutics (VTVT) stake by 15% in Q2 2026, buying an estimated $55.5K and bringing the position to 12,266 shares worth $462K. The position accounts for ﹤0.01% of the portfolio, ranked #3613.

State Street first reported a position in VTVT in Q4 2015 and has held it in 26 quarters since. The position peaked at $786K in Q1 2021. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • State Street held 12,266 shares of vTv Therapeutics worth $462K as of Q2 2026.
  • State Street bought 1,600 vTv Therapeutics shares in Q2 2026, an estimated $55.5K.
  • vTv Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3613 holding.
  • State Street first reported a position in vTv Therapeutics in Q4 2015 and has held it in 26 quarters since.
  • State Street's vTv Therapeutics position peaked at $786K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.